Clozapine
- Generic Name
- Clozapine
- Brand Names
- Clozaril, Fazaclo, Versacloz
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19ClN4
- CAS Number
- 5786-21-0
- Unique Ingredient Identifier
- J60AR2IKIC
- Background
Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine receptors results in fewer extrapyramida...
- Indication
Clozapine is indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, Clozapine should be used only in patients who have failed to respond adequately to standard antipsychotic treatment.
...
- Associated Conditions
- Suicidal Behaviour, Treatment Resistant Schizophrenia, Advanced dopaminomimetic psychosis
- Associated Therapies
- -
Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- Harvard Medical School (HMS and HSDM)
- Target Recruit Count
- 32
- Registration Number
- NCT00169091
- Locations
- 🇺🇸
Commonwealth Research Center, Jamaica Plain, Massachusetts, United States
Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- Harvard Medical School (HMS and HSDM)
- Target Recruit Count
- 38
- Registration Number
- NCT00169065
- Locations
- 🇺🇸
Commonwealth Research Center, Jamaica Plain, Massachusetts, United States
A Long Term Study of Clozapine in Patients With Treatment-resistant Schizophrenia
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 19
- Registration Number
- NCT00154258
Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay
- Conditions
- First Posted Date
- 2003-07-22
- Last Posted Date
- 2005-06-24
- Target Recruit Count
- 50
- Registration Number
- NCT00065273
- Locations
- 🇺🇸
University of Kansas, Lawrence, Kansas, United States
Treating Drug-Resistant Childhood Schizophrenia
- First Posted Date
- 2002-11-13
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 41
- Registration Number
- NCT00048828
- Locations
- 🇺🇸
Sagamore Children's Psychiatric Center, Dix Hills, New York, United States
🇺🇸Bronx Children's Psychiatric Center, Bronx, New York, United States
🇺🇸Long Island Jewish Medical Center, Glen Oaks, New York, United States
Electroconvulsive Therapy in Clozapine Refractory Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2002-07-26
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 39
- Registration Number
- NCT00042224
- Locations
- 🇺🇸
Zucker Hillside Hospital, Glen Oaks, New York, United States
Clozapine vs. Placebo in Treatment-Refractory Bipolar Disorder in Children and Adolescents
- Conditions
- First Posted Date
- 2002-05-13
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 116
- Registration Number
- NCT00036582
- Locations
- 🇺🇸
National Institute of Mental Health (NIMH), Bethesda, Maryland, United States
Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression
- Conditions
- First Posted Date
- 2002-03-01
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 60
- Registration Number
- NCT00031317
- Locations
- 🇺🇸
National Institute of Mental Health (NIMH), Bethesda, Maryland, United States
Clozapine for Treatment-Resistant Mania
- Conditions
- First Posted Date
- 2002-01-14
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 42
- Registration Number
- NCT00029458
- Locations
- 🇺🇸
National Institute of Mental Health (NIMH), Bethesda, Maryland, United States
CATIE- Schizophrenia Trial
- Conditions
- First Posted Date
- 2001-04-09
- Last Posted Date
- 2015-06-17
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 1600
- Registration Number
- NCT00014001
- Locations
- 🇺🇸
Staten Island University Hospital, Staten Island, New York, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Northwestern Medical School Department of Psychiatry, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.